Omnicell, Inc. (NASDAQ:OMCL) Short Interest Update

Omnicell, Inc. (NASDAQ:OMCL) was the recipient of a significant increase in short interest in November. As of November 30th, there was short interest totalling 2,120,000 shares, an increase of 55.9% from the November 15th total of 1,360,000 shares. Based on an average daily trading volume, of 572,300 shares, the days-to-cover ratio is currently 3.7 days.

Insider Buying and Selling at Omnicell

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total value of $567,600.00. Following the transaction, the director now owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 2.64% of the company’s stock.

Institutional Trading of Omnicell

Large investors have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. lifted its stake in Omnicell by 61.3% in the second quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company’s stock valued at $16,240,000 after acquiring an additional 228,093 shares during the last quarter. Pier Capital LLC acquired a new stake in Omnicell in the third quarter valued at $5,859,000. Federated Hermes Inc. lifted its stake in Omnicell by 1,113.6% in the second quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock valued at $26,830,000 after acquiring an additional 909,480 shares during the last quarter. Royce & Associates LP bought a new position in shares of Omnicell in the third quarter valued at about $811,000. Finally, Intech Investment Management LLC bought a new position in shares of Omnicell in the third quarter valued at about $753,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on OMCL. Wells Fargo & Company lifted their price target on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research note on Monday, October 14th. JPMorgan Chase & Co. increased their target price on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Craig Hallum increased their target price on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Benchmark restated a “buy” rating and set a $48.00 target price on shares of Omnicell in a report on Wednesday, October 9th. Finally, StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a report on Tuesday. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $52.00.

Omnicell Price Performance

OMCL stock traded up $0.05 during trading hours on Friday, reaching $46.01. The stock had a trading volume of 296,981 shares, compared to its average volume of 535,995. The stock has a market capitalization of $2.13 billion, a PE ratio of -117.46, a price-to-earnings-growth ratio of 35.72 and a beta of 0.77. The stock has a 50-day simple moving average of $45.25 and a 200 day simple moving average of $38.90. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $55.74.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.